Day: June 7, 2023

International Dialogue Centre’s Secretary General Calls for Continued Commitment to Universal Peace through Interreligious Dialogue in Audience with Pope Francis

Rome, Italy, June 07, 2023 (GLOBE NEWSWIRE) — Today, His Holiness Pope Francis received His Excellency, Dr. Zuhair Alharthi, Secretary General, International Dialogue Centre, KAICIID. The Secretary General expressed gratitude for the Vatican’s historical role in helping to establish and support the International Dialogue Centre’s interreligious and intercultural dialogue programmatic

Read More   →

Mattermost Announces “Customer-Controlled AI Architecture” for Enhancing Operational Workflows in Defense, Government and Technology Organizations

Self-hosted, open source solution enables AI-augmentation of mission-critical operations while maintaining full data control and avoiding vendor lock-in Palo Alto, CA, June 07, 2023 (GLOBE NEWSWIRE) — Mattermost, Inc., the leading secure collaboration platform for technical teams, today announced a new “Customer-Controlled AI Architecture” enabling defense, government and technology enterprises

Read More   →

Ai-Media s’apprête à lancer sa solution de sous-titrage automatique optimisée par l’IA sur le marché asiatique lors de BroadcastAsia

SYDNEY, Australie, 07 juin 2023 (GLOBE NEWSWIRE) — Ai-Media, le leader des solutions de sous-titrage, de transcription et de traduction en direct axées sur la technologie, a le plaisir d’annoncer sa présence à BroadcastAsia, à Singapour, où la société dévoilera sa solution de sous-titrage révolutionnaire LEXI 3.0 au marché asiatique. Précédemment lancée

Read More   →

Dave & Buster’s abrirá 20 lojas na Índia e na Austrália

O destino de entretenimento anunciou uma parceria da franquia internacional com o Malpani Group e a NightOwl Entertainment DALLAS, June 06, 2023 (GLOBE NEWSWIRE) — A Dave & Buster’s, o destino final de alimentos, bebidas e entretenimento, anunciou o fechamento de mais dois acordos significativos para seus planos de expansão

Read More   →

NRx Pharmaceuticals, Lotus Pharmaceuticals e Alvogen Inc. anunciam colaboração para desenvolver e comercializar o NRX-101

NRx Pharmaceuticals, Lotus Pharmaceuticals e Alvogen irão colaborar no desenvolvimento e comercialização futuros de NRX-101 para tratar a depressão bipolar com tendência suicida resistente ao tratamento (S-TRBD) para os mercados globais A Lotus Pharmaceuticals vai adquirir os direitos mundiais para o NRX-101 para a S-TRBD, e será responsável pela comercialização

Read More   →

RECENT POST